Publications

5166 Results

Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

Authors
M Huynh-Le;R Karunamuni;C Fan;L Asona;W Thompson;M Martinez;C Tangen;D Albanes;I Mills;O Andreassen;A Dale;T Seibert
Journal / Conference
Prostate Cancer and Prostatic Diseases Feb 12. doi: 10.1038/s41391-022-00497-7
Year
2022
Research Committee(s)
Cancer Control and Prevention and Epidemiology
PMID
PMID35152271
Study Number(s)
SWOG-9217

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

Authors
H Safran;K Winter;D Ilson;D Wigle;T DiPetrillo;M Haddock;T Hong;L Leichman;L Rajdev;M Resnick;L Kachnic;S Seaward;H Mamon;D Diaz Pardo;C Anderson;X Shen;A Sharma;A Katz;J Salo;K Leonard;J Moughan;C Crane
Journal / Conference
Lancet Oncology Feb;23(2):259-269
Year
2022
Research Committee(s)
Gastrointestinal
PMID
PMID35038433
Study Number(s)
CTSU/R1010

Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis

Authors
NJ McCleary;S Zhang;C Ma;F Ou;T Bainter;A Venook;D Niedzwiecki;H-J Lenz;F Innocenti;B O'Neil;H Hochster;J Atkins;R Goldberg;K Ng;R Mayer;CD Blanke;E O'Reilly;C Fuchs;J Meyerhardt
Journal / Conference
Journal of Geriatric Oncology Jan 29:S1879-4068(22)00007-8, 2022
Year
2022
Research Committee(s)
Gastrointestinal
PMID
PMID35105521
Study Number(s)
CTSU/C80405

Associations of Inflammatory Biomarkers with Survival Among Patients with Stage III Colon Cancer (CALGB/SWOG 80702 [Alliance])

Authors
E Cheng;Q Shi;A Shields;N Rifai;E Feliciano;J Meyers;A Nixon;A Shegrill;K Guthrie;F Couture;P Kuebler;J Bendell;P Kumar;D Lewis;B Tan;E O'Reilly;J Brown;P Philip;B Caan;J Meyerhardt
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer

Authors
E Gonzalez-Kozlova;H-H Huang;M Redman;R Herbst;S Gettinger;L Bazhenova;H Xie;M Patel;K Nie;J Harris;K Argueta;D Del Valle;S Kim-Schulze;S Gnjatic
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I

Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial

Authors
E Parra;J Zhang;M Redman;R Lazcano;M Piubelli;C Laberiano Fernandez;R Pandurengan;S Zhang;H Chen;G Manyam;D Duose;J Zhang;G Al-Atrash;R Herbst;K Kannan;E Gonzalez-Kozlova;S Gnjatic;I Wistuba;S Gettinger;L Bazhenova;J Lee;J Zhang;C Haymaker
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I

Immune Gene Expression Signatures associated clinical benefit from Nivolumab/Ipilimumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer: an immune biomarker analysis of Phase III SWOG Lung-MAP S1400I trial

Authors
D Duose;J Zhang;M Redman;B Zhang;R Luthra;G Al-Atrash;R Herbst;E Gonzalez-Kozlova;S Gnjatic;I Wistuba;S Gettinger;L Bazhenova;J Lee;J Zhang
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), poster
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1400I

SWOG S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy

Authors
A VanderWalde;J Moon;K Kendra;N Khushalani;F Collichio;J Sosman;A Ikeguchi;A Victor;T-G Truong;B Chmielowski;D Portnoy;M Wu;K Grossmann;A Ribas
Journal / Conference
American Association for Cancer Research (April 8 - 13, 2022 New Orleans, LA), plenary, oral
Year
2022
Research Committee(s)
Melanoma
Study Number(s)
S1616

Circulating tumor DNA dynamics on front line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: a biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial

Authors
K Raghav;F-S Ou;A Venook;F Innocenti;R Sun;H-J Lenz;S Kopetz
Journal / Conference
ASCO Gastrointestinal Cancer Symposium (Jan 20-22, 2022, San Francisco, CA), poster session, Abst #193
Year
2022
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Alliance A031902 (CASPAR): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC)

Authors
A Rao;C Ryan;J VanderWheele;G Heller;L Lewis;A Tan;C Watt;R Chen;M Kohli;P Barata;B Gartrell;R Grubb;A Dueck;Y Wen;M Morris
Journal / Conference
J Clin Oncol 40, 2022 (suppl 6; abstr TPS194); ASCO Genitourinary (GU) Cancers Symposium 2022 (Feb 17-19, 2022, San Francisco, CA)
Year
2022
Research Committee(s)
Genitourinary